Loading live market data…

Anteris Technologies Global Corp.

NASDAQ:AVR

$8.95 USD

-$0.41 (-4.38%)

Volume
790.55K
Average Volume
1.19M
Market Capitalization
$329.26M
P/E Ratio
-2.24
Dividend Yield
0.00%
Price Target
$16.50
Year High
$11.06
Year Low
$2.85
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$20.93

Industry, Sector & symbol

Stock Exchange NASDAQ
CEO Wayne Geoffrey Paterson
Industry Medical - Devices
Sector Healthcare
Current Symbol AVR
CUSIP 03675P102
CIK 0002011514
Web https://anteristech.com
Phone 61 13 0055 0310
Currency USD
Employees 174
Country AU

Liquidity

Debt-to-Equity Ratio 0.01
Payout Ratio 0.00
Current Ratio 20.93
Quick Ratio 20.93
Cash Ratio 20.68

Sales & Book Value

Annual Sales $1.91M
Price / Sales 177.88
Cash Flow -3.68
Price / Cash Flow -3.80
Price / Book 0.76

Price Target and Rating

Average Stock Price Forecast $16.50
High Stock Price Forecast $18.00
Low Stock Price Forecast $15.00
Forecast Upside/Downside -45.76%
Consensus Rating Sell
Rating Score(0-5) 2
Research Coverage 2 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-4
Trailing P/E Ratio -2.24
PEG Ratio 0.07
P/E Growth 0.07
Net Income $-94.14M
Net Margin -5148.78%
Pretax Margin -5116.15%
Return on Equity -124.40%
Return on Assets -32.34%

Financials Score

AltmanZ Score 10.86
Piotroski Score 3.00
Working Capital 272.98M
Total Assets 294.72M
Ebit -94.63M
Market Cap 344.34M
Total Liabilities 16.31M

Poll Results

About Anteris Technologies Global Corp. (NASDAQ:AVR) Stock

Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatu ... s, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.

Pennon returns to profit after water bill hikes

2026-06-10 03:51:00

Pennon Group PLC (LSE:PNN, OTC:PEGRY) returned to the black in its latest financial as higher regulatory allowances and increased water consumption boosted...

Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance

2026-06-08 06:00:00

MINNEAPOLIS and BRISBANE, Australia, June 08, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory clearance from the French National Agency for Medicines and Health Products Safety (ANSM) for the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial in patients with severe calcific aortic stenosis (the “PARADIGM Trial”). This authorization marks a significant milestone in the Company's clinical and regulatory strategy and enables patient recruitment to commence at leading centers in France.

Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors

2026-05-13 08:39:00

MINNEAPOLIS and BRISBANE, Australia, May 13, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced the appointment of Ms. Susan Knight and Mr.

Anteris adds Susan Knight, Stephen Denaro to board as company advances heart valve strategy

2026-05-13 07:48:00

Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has strengthened its board with the appointments of experienced healthcare and finance executive Susan...

Anteris advances PARADIGM trial as Q1 cash burn reflects commercialisation push

2026-05-13 06:43:00

Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has reported strong operational progress for the March 2026 quarter as the company advanced recruitment...

Anteris Announces Results for the First Quarter of 2026

2026-05-12 19:00:00

MINNEAPOLIS and BRISBANE, Australia, May 12, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update.

Anteris Announces Results for the First Quarter of 2026

2026-05-12 19:00:00

MINNEAPOLIS and BRISBANE, Australia, May 12, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. Q1 2026 Highlights Completed aggregate capital raises totalling $320 million in January 2026 to support execution of the PARADIGM Trial and advance the Company toward global commercialization of the DurAVR® THV System Advanced PARADIGM Trial recruitment, supported by ongoing regulatory and operational work to activate additional countries and sites – post quarter-end, U.S. enrollment commenced Presented clinical data from the ongoing EMBARK Study and U.S. Early Feasibility Study (EFS) at Cardiovascular Research Technologies (CRT 2026) and Sydney Valves 2026, supporting ongoing scientific engagement and exchange with the clinical community “Q1 2026 reflects strong execution across the PARADIGM Trial, with patient enrollment ongoing in Europe and continued progress on key recruitment activities globally.

Whirlpool cuts forecast, suspends dividend as Iran war hammers demand

2026-05-07 08:22:00

Whirlpool Corporation (NYSE:WHR) reported a steep first-quarter loss and slashed its full-year outlook, citing rapid deterioration in macroeconomic...

Frequently Asked Questions

What is the current Anteris Technologies Global Corp. (AVR) stock price?

Anteris Technologies Global Corp.(NASDAQ:AVR) stock price is $8.95 in the last trading session. During the trading session, AVR stock reached the peak price of $11.055 while $2.85 was the lowest point it dropped to. The percentage change in AVR stock occurred in the recent session was --4.38% while the dollar amount for the price change in AVR stock was -$-0.41.

AVR's industry and sector of operation?

The NASDAQ listed AVR is part of Medical - Devices industry that operates in the broader Healthcare sector.

Who are the executives of AVR?

David Denis | President & Director
Chris Meduri | Chief Medical Officer & Member of Medical Advisory Board
Matthew McDonnell | Chief Financial Officer
Wayne Geoffrey Paterson | Vice Chairman & Chief Executive Officer
|

How many employees does AVR have?

Number of AVR employees currently stands at 174. AVR operates from Toowong Tower, Toowong, QLD 4066, AU.

Link for AVR official website?

Official Website of AVR is: https://anteristech.com

How do I contact AVR?

AVR could be contacted at phone #61 13 0055 0310 and can also be accessed through its website. AVR operates from Toowong Tower, Toowong, QLD 4066, AU.

How many shares of AVR are traded daily?

The average number of AVR shares traded daily for last 3 months was 1.19M.

What is the market cap of AVR currently?

The market value of AVR currently stands at $329.26M with its latest stock price at $8.95